From ethanol to propylene glycol: A safer future for carmustine

Abstract

Keywords

Carmustine ethanol propylene glycol toxicity formulation

Get full access to this article

View all access options for this article.

References

Kumar

, et al. Blood alcohol levels after carmustine infusion: clinical implications. Clin Pharmacol Ther 2015; 98: 175–180.

Jones

, et al. Ethanol in chemotherapy formulations: effects on neurotoxicity. J Oncol Pharm Pract 2017; 23: 295–302.

Lee

Chen

. Ethanol-drug interactions in cancer patients: a pharmacokinetic perspective. Drug Metab Rev 2020; 52: 45–58.

Valeur

Hertel

Lundstrøm

, et al. The cumulative daily tolerance levels of potentially toxic excipients ethanol and propylene glycol are commonly exceeded in neonates and infants. Basic Clin Pharmacol Toxicol 2018; 122: 523–530.

Miller

, et al. Ethanol exposure risks in oncology patients with liver disease. Liver Int 2016; 36: 1013–1020.

Olivieri

, et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietic stem cell transplantation in lymphoma: an observational study on 1038 patients from Fondazione Italiana Linfomi. Biol Blood Marrow Transplant 2018; 24: 1814–1822.

Patel

, et al. Propylene glycol toxicity in chemotherapy: case reports and review. J Clin Oncol 2019; 37: e19001.

Nguyen

, et al. Renal impairment and propylene glycol accumulation in chemotherapy patients. Nephrol Dial Transplant 2021; 36: 695–702.

Vigneron

Astier

Trittler

, et al. SFPO And ESOP recommendations for the practical stability of anticancer drugs: an update. Ann Pharm Fr 2013; 71: 376–389.

10.

Knoll

, et al. Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature. Eur J Hosp Pharm 2023; 30: 11–16.

11.

Vivus, Inc. VIVUS announces enrollment of 1st patient in Phase 2 trial assessing ethanol-free carmustine as component of high-dose chemotherapy prior to transplant in patients with Hodgkin or Non-Hodgkin lymphoma [press release]. 2025. Available at: https://www.vivus.com/pdf/press-releases/2025-04-14 VIVUS_Announces_Enrollment_of_1st_Patient_Phase_2_Trial.pdf (Accessed: 23 September 2025).